⌕
Viking Therapeutics · VKTX · Nasdaq
Tenet 36 · Weak
Compare
$26.88+0.30%At closeTenet 36 · Weak
$26.88+0.08 (+0.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Viking Therapeutics (VKTX) Institutional Ownership

13F filers reported holding 7.4% of Viking Therapeutics (VKTX) shares as of Sep 30, 2026, across 198 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
7.4%
Sep 30, 2026
13F filers
198
quarter ended Sep 30, 2026
13F value
$305.6M
9.4M shares
Quarter's fund flow
Mild accumulation
29 new · 24 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (29 new · 66 increased · 52 reduced · 24 closed · 27 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 198 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Aug 1, 2026Kelly-Gemmell Dorothy ElizabethdirectorAcquired · Grant / award6,333—↗
Aug 1, 2026Kelly-Gemmell Dorothy ElizabethdirectorAcquired · Grant / award40,800Stock Option (Right to Buy)—↗
Jul 29, 2026Lian BrianPresident & CEODisposed · Open-market sale148,517$33.32↗
Jul 29, 2026ZANTE GREGChief Financial OfficerDisposed · Open-market sale21,217$33.47↗
Jul 29, 2026Mancini MariannaChief Operating OfficerDisposed · Open-market sale18,217$33.47↗
Jul 28, 2026Lian BrianPresident & CEOAcquired · Grant / award221,667—↗
Jul 28, 2026ZANTE GREGChief Financial OfficerAcquired · Grant / award31,667—↗
Jul 28, 2026Mancini MariannaChief Operating OfficerAcquired · Grant / award31,667—↗
Jun 1, 2026Chen Hubert CChief Medical OfficerAcquired · Grant / award190,000Stock Option (Right to Buy)—↗
Mar 10, 2026Aubuchon Neil WilliamChief Commercial OfficerAcquired · Open-market buy4,475$33.50↗
Jan 12, 2026Aubuchon Neil WilliamChief Commercial OfficerAcquired · Grant / award180,000Stock Option (Right to Buy)—↗
Jan 5, 2026ZANTE GREGChief Financial OfficerDisposed · Open-market sale31,961$32.30↗
Jan 5, 2026ZANTE GREGChief Financial OfficerDisposed · Open-market sale13,900$33.38↗
Jan 5, 2026ZANTE GREGChief Financial OfficerDisposed · Open-market sale10,300$34.24↗
Jan 5, 2026ZANTE GREGChief Financial OfficerDisposed · Open-market sale1,500$32.09↗
Jan 5, 2026Mancini MariannaChief Operating OfficerDisposed · Open-market sale31,961$32.29↗
Jan 5, 2026Mancini MariannaChief Operating OfficerDisposed · Open-market sale13,600$33.37↗
Jan 5, 2026Mancini MariannaChief Operating OfficerDisposed · Open-market sale10,500$34.22↗
Jan 5, 2026Mancini MariannaChief Operating OfficerDisposed · Open-market sale1,600$35.07↗
Jan 5, 2026Lian BrianPresident & CEODisposed · Open-market sale132,454$32.29↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Viking Therapeutics do institutions hold?

13F filers reported holding 7.4% of Viking Therapeutics' shares as of Sep 30, 2026, across 198 filers.

How many 13F filers hold Viking Therapeutics?

Viking Therapeutics was held by 198 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.